Covering the whole development process for the global biotechnology industry
Biopharmaceutical innovation is alive and well. An ever-widening array of product modalities is taking the industry beyond proteins to genes, cells, and tissues â€” beyond monoclonal antibodies to fragments, bispecifics, and antibodyâ€“drug conjugates â€” beyond live/attenuated vaccines to recombinant proteins, nucleic acids, and immunotherapies. Biosimilar developers are introducing competition that pushes innovators beyond traditional modalities and delivery methods. Authors, reader-survey respondents, and editorial advisors will help us examine trends in regenerative and personalized medicine, fusion proteins, developability assessments, exosomes, and more.